JCR Pharma Corporation
Basic information
- Head office
- 3-19 Kasugacho, Ashiya-shi, Hyogo Prefecture
- Chief executive
- Hiroyuki Sonoda
- Capital
- 9,061,860,000 (90 100 million)
- Employees (non-consolidated)
- 937 people
- Employees (consolidated)
- 985 people
- Start date
- 1975-09-13
- End date
Websites
Business
Related companies
| Company name | Group | Parent | Subsidiary | Customer | Supplier | Alliance | Bank | Shareholder |
|---|---|---|---|---|---|---|---|---|
|
|
||||||||
| ArmaGen, Inc. | ||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
|
|
Network
History
In 1975, founder Shin Ashida was responsible for the purification project of urokinase at the pharmaceutical company where he was working at the time.![]()
Launched 'Agalsidase Beta BS Intravenous Infusion JCR,' as the company's first lysosomal storage disorder enzyme therapy![]()
Started business activities for clinical operations, regulatory affairs, and development in Brazil through 'JCR DO BRASIL FARMACÊUTICOS IMPORTAÇÃO E EXPORTAÇÃO LTDA.'![]()
Co-developed the smartphone application 'Melon Diary®' with PHC Corporation for the 'Growject®' dedicated injector 'Growject®L'![]()
Signed a contract with AstraZeneca K.K. for domestic manufacturing of the COVID-19 vaccine 'AZD1222'![]()
Launched the genetically engineered Mucopolysaccharidosis Type II treatment 'Izargo®: Intravenous infusion 10mg' in Japan![]()
Received the New Treatment Award at 'WORLDSymposium™ 2022' for the genetically engineered Mucopolysaccharidosis Type II treatment 'Izargo®: Intravenous infusion'![]()
Transitioned from the First Section to the Prime Market of the Tokyo Stock Exchange due to market classification review![]()
Established 'JCR Luxembourg S.A.' as the European base for global distribution management in the Grand Duchy of Luxembourg![]()
Established 'JCR Europe B.V.' in the Netherlands as the global clinical development management company![]()
Acquired shares of Taiwan-based biopharmaceutical manufacturing and development contract company "Mycenax Biotech Inc."![]()
Obtained approval for the efficacy addition of recombinant human growth hormone preparation "Growject®" for short stature in SHOX deficiency without epiphyseal closure![]()
News
There is no news.
Public records
National Tax Agency basic information6140001000905
- Trade name
- JCRファーマ株式会社
- Trade name (kana)
- ジェーシーアールファーマ
- Name in English
- Corporation type
- 301
- Address
- 〒659-0021 兵庫県芦屋市春日町3番19号
- Postal code
- 6590021
- Prefecture code
- 28
- City code
- 206
- Address outside Japan
- Prefecture in English
- City in English
- Address outside Japan in English
- Corporate number assignment date
- 2015-10-05
- Update date
- 2020-04-17
- Change date
- 2020-04-06
- Registry closure date
- Reason for registry closure
- Successor corporate number
- Details of the change
- 令和2年4月1日神戸市西区室谷一丁目2番3号株式会社ファミリーヘルスレンタル(7140001010523)を合併
- Latest record
- 1
- Excluded from search
- 0
- Processing type
- 71
- Correction type
- 0
- Trade name image ID
- Address image ID
- Sequence number
- 4575236
METI gBizINFO6140001000905
- Corporate number
- 6140001000905
- Trade name
- JCRファーマ株式会社
- Trade name (kana)
- ジェーシーアールファーマ
- Trade name (alphabet)
- Registry closure date
- Reason for registry closure
- Registered address
- 兵庫県芦屋市春日町3番19号
- Postal code
- 6590021
- Prefecture
- 兵庫県
- Prefecture code
- 28
- City or district
- 芦屋市
- City code
- 206
- Street address
- 春日町3番19号
- Organisation type
- 301
- Processing type
- 71
- Correction type
- 0
- Status
- Representative
- 代表取締役社長 薗田 啓之
- Capital
- 9061000000
- Employees
- 938
- Employees (male)
- 546
- Employees (female)
- 391
- Business summary
- 医薬品、再生医療等製品およびその原料の製造、売買ならびに輸出入医療用機器および実験用機器の売買ならびに輸出入
- Website URL
- http://www.jcrpharm.co.jp/
- Year founded
- Business category
- E:製造業
- Date established
- Unified government qualification - grade
- Unified government qualification - business items
- Update date
- 2020-04-17
- Key information
- 6140001000905